Welcome back to Fast Money Insad trading at highs not seen in a quarter of a century after the company clinched FDA approval for its first-in-class drug treating a form of chronic lung disease. The company estimating the drug could top $5 billion in peak sales for this indication alone with a patient population of as many as 500,000 in the US. Joining us on the set for more is INSMAD CEO Will Lewis.Will, welcome back. Congratulations on the FDA approval. This is the first DPP1 inhibitor for non-cystic fibro ...

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —— BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB —— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network —— Insmed to Host Investor Conference Call Today at 12:00 PM ET  —BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Ins ...